We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · September 29, 2019

Oral Semaglutide vs Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin

Diabetes Care

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Diabetes Care 2019 Sep 17;[EPub Ahead of Print], HW Rodbard, J Rosenstock, LH Canani, C Deerochanawong, J Gumprecht, SØ Lindberg, I Lingvay, AL Søndergaard, MB Treppendahl, E Montanya

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading